InvestorsHub Logo
Followers 42
Posts 4850
Boards Moderated 0
Alias Born 08/06/2012

Re: None

Friday, 05/26/2017 11:05:56 AM

Friday, May 26, 2017 11:05:56 AM

Post# of 144812
PHARMACYTE AND SEC INVESTIGATIONS The request from the SEC is contained in a memorandum filed on May 4, 2017, in the Central District of California. The document describes how Mr. Coldicutt, who works from an office in San Diego, has been the lawyer for five IPOs that drew some scrutiny from SEC investigators. (The companies are AppointMed Inc., Axeture Corp., IWEB Inc., PharmaCyte Biotech Inc. and ROID Group Inc.) According to the SEC, the companies are run by an undisclosed control person or promoter. The regulator does not provide any hints as to the identity of that person.

>>Where is Bio btw?<<

The SEC also says that Mr. Coldicutt may have played a significant role in fraudulent share issuances. He has written false and misleading opinion letters as part of share offerings, according to the memorandum. The SEC claims to have information showing undisclosed affiliations between shareholders of one of the companies, PharmaCyte.
The memorandum provides few other details of the allegations, as its purpose is to elicit the production of documents from Mr. Coldicutt. As part of its investigation into the companies, the SEC issued subpoenas requesting his records. Among other things, the regulator sought letters showing who had hired him as well as bank records. According to the memorandum, Mr. Coldicutt eventually produced some documents, but refused to send in everything. He claimed that the remaining documents were subject to lawyer-client privilege, legal-speak for confidential.


https://www.pressreader.com/canada/stockwatch-daily/20170508/281509341095076

Disclosure: I am involved in and support the SEC whistleblower program, I may be rewarded cash for information that leads to the successful enforcement by the SEC of a federal court or administrative action of 1m+.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News